Yutong Wang

Serum S100A12 Levels Are Correlated With the Presence and Severity of Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus

Objective Patients with type 2 diabetes mellitus (T2DM) are at high risk for development of atherosclerosis and cardiovascular events. Serum S100A12 levels have been reported to be associated with coronary artery disease (CAD) and T2DM. We sought to assess whether serum S100A12 levels are correlated with the presence and severity of CAD. Methods Type 2 diabetes mellitus levels in 188 consecutive patients with T2DM undergoing coronary angiography for the evaluation of CAD. The severity of CAD was assessed by the Coronary Atherosclerosis Index (CAI) scores. Results Serum S100A12 levels were significantly higher in patients with T2DM with CAD than in those without CAD. Multivariate logistic regression analysis revealed that serum S100A12 levels were independently associated with the presence of CAD. Serum S100A12 levels were positively correlated with the Coronary Atherosclerosis Index scores after adjusting for other clinical characteristics. Conclusion High S100A12 levels are associated with the presence and severity of CAD in patients with T2DM.

Exogenous melatonin in the treatment of pain: a systematic review and meta-analysis

Melatonin is an important hormone for regulating mammalian circadian biology and cellular homeostasis. Recent evidence has shown that melatonin exerts anti-nociception effects in both animals and humans. However, according to clinical trials, the anti-nociception effects of melatonin are still controversial. The aim of this meta-analysis was to investigate the anti-nociception effects of melatonin premedication. The primary outcome was the effects of melatonin on pain intensity. The secondary outcomes included the number of patients with analgesic requirements, total analgesic consumption, and brain-derived neurotrophic factor (BDNF) levels. In total, 19 studies were included in the current meta-analysis. The pooling data show that melatonin significantly decreased the pain intensity, as evidenced by the pain scores. Moreover, melatonin administration also reduced the proportion of patients with analgesic requirements and BDNF levels. However, the effects of melatonin on total analgesic consumption still require further confirmation. Collectively, the current meta-analysis supports the use of melatonin for anti-nociception.